{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:58:10Z","timestamp":1786121890942,"version":"build-2736575974"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the real\u2010world associations between semaglutide 2.4\u2009mg and cardiometabolic comorbidities, biomarkers and cardiovascular risk among adults with overweight or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used US claims data and laboratory measurements from the Komodo Research Database (2016\u20132024). Adults with obesity or with overweight and \u2265\u20091 obesity\u2010related comorbidity were included. Patients on semaglutide 2.4\u2009mg for \u2265\u200912\u2009months were compared with non\u2010users (including users of other obesity medications) using propensity score weighting with residual imbalances adjusted in regression model. Outcomes included time to onset of cardiometabolic comorbidities, change in cardiometabolic biomarkers and changes in 10\u2010year ASCVD risk score at 12\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      25\u2009783 semaglutide 2.4\u2009mg users and 8\u2009948\u2009913 non\u2010users were identified. Semaglutide 2.4\u2009mg was associated with significantly lower risks for incident prediabetes or type 2 diabetes, type 2 diabetes only, hypertension, ASCVD, heart failure and CVD (HRs 0.45\u20130.75; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), as well as greater improvements in BMI (\u22124.1\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), SBP (\u22126.2\u2009mmHg), HbA1c (\u22120.4%), LDL cholesterol (\u22127.7\u2009mg\/dL), triglycerides (\u221228.6\u2009mg\/dL) and HDL cholesterol (+1.9\u2009mg\/dL; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). At 12\u2009months, semaglutide 2.4\u2009mg users (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009161) demonstrated a greater reduction in ASCVD risk score (\u22120.7% vs. +0.3%; between\u2010group difference \u22121.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with a decrease in the proportion at intermediate\u2010high ASCVD risk (14.9%\u20139.3% vs. 17.7%\u201318.7%; OR 0.3 [95% CI: 0.1, 0.6],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Semaglutide 2.4\u2009mg was associated with lower risk of multiple cardiometabolic comorbidities, favourable changes in biomarkers, and lower estimated ASCVD risk in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70746","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:17:47Z","timestamp":1777349867000},"page":"6121-6130","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide\n                    <scp>2.4\u2009mg<\/scp>\n                    Cardiometabolic Long\u2010Term Effects in Patients With Obesity or Overweight in a Real\u2010World Setting: A Retrospective Cohort Study in the United States (\n                    <scp>SMILE<\/scp>\n                    )"],"prefix":"10.1111","volume":"28","author":[{"given":"Aleksandrina","family":"Ruseva","sequence":"first","affiliation":[{"name":"Novo Nordisk Inc  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3390-0182","authenticated-orcid":false,"given":"Wojciech","family":"Michalak","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bassan","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella Xiaoyan","family":"Du","sequence":"additional","affiliation":[{"name":"Analysis Group Inc  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Fabricatore","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Br\u00edain \u00d3","family":"Hartaigh","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Man","sequence":"additional","affiliation":[{"name":"Analysis Group Inc  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ramasubramanian","sequence":"additional","affiliation":[{"name":"Analysis Group Inc  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pangsibo","family":"Shen","sequence":"additional","affiliation":[{"name":"Analysis Group Inc  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Song","sequence":"additional","affiliation":[{"name":"Analysis Group Inc  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Lopez\u2010Jimenez","sequence":"additional","affiliation":[{"name":"Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases \u201cOverweight & Obesity Statistics \u201daccessed August 18 2025 https:\/\/www.niddk.nih.gov\/health\u2010information\/health\u2010statistics\/overweight\u2010obesity."},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2010.172"},{"key":"e_1_2_13_4_1","volume-title":"Endotext [Internet]","author":"Feingold K.","year":"2000"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031882"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2010.04.012"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199003293221303"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026560"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60105-0"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020245"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae025"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.10.004"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2021.12.008"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31982"},{"key":"e_1_2_13_15_1","unstructured":"United States Food and Drug Administration \u201cHighlights of Prescribing Information: WEGOVY (Semaglutide) \u201daccessed August 17 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf."},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14890"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.005"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1785"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.737"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03320-6"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70080"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16370"},{"key":"e_1_2_13_29_1","unstructured":"American Heart Association \u201cThe American Heart Association PREVENT Online Calculator \u201daccessed January 31 2026 https:\/\/professional.heart.org\/en\/guidelines\u2010and\u2010statements\/prevent\u2010calculator."},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0666-6"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70746","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:33:12Z","timestamp":1786087992000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/dom.70746"],"URL":"https:\/\/doi.org\/10.1111\/dom.70746","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70746\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70746\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70746\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70746\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70746\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70746\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70746\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70746\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70746\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70746\/v1\/review3","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"2025-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}